Keyphrases
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Patients with Diabetes
100%
Ancillary
100%
Without Diabetes
100%
Cardiovascular Phenotype
100%
Diabetic Patients
85%
Exercise Capacity
71%
Heart Failure
28%
Non-diabetic
28%
Sildenafil
28%
Hospitalization Risk
14%
Hospitalization
14%
Placebo
14%
Renal Disease
14%
Comorbidity
14%
Clinical Features
14%
High Incidence
14%
Clinical Status
14%
Adverse Outcomes
14%
Exercise Test
14%
C-reactive Protein
14%
High Prevalence
14%
Ventricular Activation
14%
Echocardiography
14%
Vascular Disease
14%
Maximal Oxygen Uptake
14%
Galectin-3 (Gal-3)
14%
6-minute Walk Distance (6MWD)
14%
Clinical Events
14%
Patients with Heart Failure
14%
Ejection Fraction
14%
Endothelin-1 (ET-1)
14%
Pulmonary Disease
14%
Uric Acid
14%
Left Ventricular Hypertrophy
14%
Phosphodiesterase Type 5 Inhibitors
14%
Natriuretic Peptides
14%
Multicenter Randomized Trial
14%
Pathophysiological Mechanisms
14%
Diastolic Heart Failure
14%
Hypertension Prevalence
14%
Pulmonary Vascular
14%
Ventricular Hypertrophy
14%
Phenotypic Characterization
14%
Cardiac Magnetic Resonance
14%
Filling Pressure
14%
Vasodilator
14%
Biomarker Panel
14%
C-terminal Telopeptide of Type I Collagen
14%
I(1)
14%
Profibrotic
14%
Entry Criteria
14%
Function Parameters
14%
Chronotropic Reserve
14%
Systolic Ventricular Function
14%
Intracardiac Pressures
14%
Health Exercise
14%
Clinical Exercise
14%
Diabetic Heart Failure
14%
Improving Health Outcomes
14%
Diastolic Ventricular Function
14%
Exercise Ability
14%
Pro-oxidative
14%
Exercise Outcomes
14%
High Fill
14%
Medicine and Dentistry
Cardiovascular System
100%
Diabetes
100%
Heart Failure with Preserved Ejection Fraction
100%
Exercise
71%
Diabetes Mellitus
42%
Congestive Heart Failure
28%
Patient with Diabetes
28%
Sildenafil
28%
Biological Marker
14%
Prevalence
14%
Oxygen Consumption
14%
Clinical Feature
14%
Placebo
14%
Exercise Test
14%
Adverse Outcome
14%
C Reactive Protein
14%
Echocardiography
14%
Silo-Filler's Disease
14%
Vascular Disease
14%
Outpatient
14%
Heart Ventricle Function
14%
Galectin 3
14%
Ventricular Hypertrophy
14%
Ejection Fraction
14%
Health Outcomes
14%
Left Ventricular Hypertrophy
14%
Natriuretic Factor
14%
Diastolic Heart Failure
14%
Cardiac Magnetic Resonance Imaging
14%
Multiple Chronic Conditions
14%
Renovascular Hypertension
14%
Chronotropism
14%
Vasoconstrictor
14%
Collagen Type 1
14%
Endothelin 1
14%
C-Terminal Telopeptide
14%
Uric Acid
14%
Phosphodiesterase V
14%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure with Preserved Ejection Fraction
100%
Diabetes Mellitus
42%
Congestive Heart Failure
28%
Sildenafil
28%
Placebo
14%
Biological Marker
14%
Adverse Outcome
14%
Prevalence
14%
C Reactive Protein
14%
Lung Disease
14%
Clinical Feature
14%
Vascular Disease
14%
Galectin 3
14%
Heart Left Ventricle Hypertrophy
14%
Natriuretic Factor
14%
Endothelin 1
14%
Heart Ventricle Hypertrophy
14%
Renovascular Hypertension
14%
Collagen Type 1
14%
Diastolic Heart Failure
14%
Phosphodiesterase V
14%
Carboxy Terminal Telopeptide
14%
Multiple Chronic Conditions
14%
Uric Acid
14%